The estimated Net Worth of Karthik Kuppusamy is at least 2.31 百万$ dollars as of 28 August 2024. Karthik Kuppusamy owns over 1,990 units of Quest Diagnostics stock worth over 1,759,644$ and over the last 2 years Karthik sold DGX stock worth over 551,387$.
Karthik has made over 2 trades of the Quest Diagnostics stock since 2024, according to the Form 4 filled with the SEC. Most recently Karthik sold 1,990 units of DGX stock worth 304,987$ on 28 August 2024.
The largest trade Karthik's ever made was selling 1,990 units of Quest Diagnostics stock on 28 August 2024 worth over 304,987$. On average, Karthik trades about 208 units every 7 days since 2023. As of 28 August 2024 Karthik still owns at least 11,459 units of Quest Diagnostics stock.
You can see the complete history of Karthik Kuppusamy stock trades at the bottom of the page.
Karthik's mailing address filed with the SEC is 500 PLAZA DRIVE, C/O QUEST DIAGNOSTICS INC, SECAUCUS, NJ, 07094.
Over the last 21 years, insiders at Quest Diagnostics have traded over 67,426,608$ worth of Quest Diagnostics stock and bought 34,000 units worth 1,910,090$ . The most active insiders traders include Plc Gsk、James F Iii Flaherty、Jeffrey M Leiden. On average, Quest Diagnostics executives and independent directors trade stock every 19 days with the average trade being worth of 3,750,703$. The most recent stock trade was executed by Michael E Prevoznik on 29 August 2024, trading 32,551 units of DGX stock currently worth 3,118,386$.
quest diagnostics (nyse: dgx) empowers people to take action to improve health outcomes. derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management. quest annually serves one in three adult americans and half the physicians and hospitals in the united states, and our 45,000 employees understand that, in the right hands and with the right context, our diagnostic insights can inspire actions that transform lives. the company offers physicians the broadest test menu (3,000+ tests), is a pioneer in developing innovative new tests, is the leader in cancer diagnostics, provides anatomic pathology (ap) services, & interpretive consultation through its medical & scientific staff of about 900 m.d.s & ph.d.s. the company reported 2014 revenues of $7.4 billion. quest diagnostics offers the most extensive clinical testing network in the u.s., with laborator
Quest Diagnostics executives and other stock owners filed with the SEC include: